BACKGROUND: The effect of MDR1 C3435T single nucleotide polymorphism (SNP) in exon 26 on digoxin pharmacokinetics has recently been challenged. OBJECTIVE. To clarify the relationships between MDR1 genetic polymorphisms in exon 26 (C3435T) and 21 (G2677T/A) and digoxin pharmacokinetics. MATERIALS AND METHODS: MDR1 genotypes for C3435T and G2677T/A SNPs were determined in 32 healthy subjects whose single oral dose digoxin pharmacokinetics had been measured over 48 h. RESULTS: A significant relationship was observed between C3435T SNP and digoxin AUCs ( p<0,05). Homozygous TT subjects had 20% higher digoxin plasma concentrations than CT and CC subjects and a trend for higher 48 h digoxin urinary recoveries (TT>CT>CC). Similar results, although not statistically significant, were observed from the MDR1 G2677T/A SNP. CONCLUSIONS: Our results confirm that the MDR1 C3435T single nucleotide polymorphism (SNP) significantly affects digoxin disposition kinetics, with homozygous TT subjects presenting the highest plasma concentrations.
BACKGROUND: The effect of MDR1C3435T single nucleotide polymorphism (SNP) in exon 26 on digoxin pharmacokinetics has recently been challenged. OBJECTIVE. To clarify the relationships between MDR1 genetic polymorphisms in exon 26 (C3435T) and 21 (G2677T/A) and digoxin pharmacokinetics. MATERIALS AND METHODS:MDR1 genotypes for C3435T and G2677T/A SNPs were determined in 32 healthy subjects whose single oral dose digoxin pharmacokinetics had been measured over 48 h. RESULTS: A significant relationship was observed between C3435T SNP and digoxin AUCs ( p<0,05). Homozygous TT subjects had 20% higher digoxin plasma concentrations than CT and CC subjects and a trend for higher 48 h digoxin urinary recoveries (TT>CT>CC). Similar results, although not statistically significant, were observed from the MDR1G2677T/A SNP. CONCLUSIONS: Our results confirm that the MDR1C3435T single nucleotide polymorphism (SNP) significantly affects digoxin disposition kinetics, with homozygous TT subjects presenting the highest plasma concentrations.
Authors: Jacques Fellay; Catia Marzolini; Emma R Meaden; David J Back; Thierry Buclin; Jean Philippe Chave; Laurent A Decosterd; Hansjakob Furrer; Milos Opravil; Giuseppe Pantaleo; Dorota Retelska; Lidia Ruiz; Alfred H Schinkel; Pietro Vernazza; Chin B Eap; Amalio Telenti Journal: Lancet Date: 2002-01-05 Impact factor: 79.321
Authors: Andreas Johne; Karla Köpke; Thomas Gerloff; Ingrid Mai; Stephan Rietbrock; Christian Meisel; Sven Hoffmeyer; Reinhold Kerb; Martin F Fromm; Ulrich Brinkmann; Michel Eichelbaum; Jürgen Brockmöller; Ingolf Cascorbi; Ivar Roots Journal: Clin Pharmacol Ther Date: 2002-11 Impact factor: 6.875
Authors: R B Kim; B F Leake; E F Choo; G K Dresser; S V Kubba; U I Schwarz; A Taylor; H G Xie; J McKinsey; S Zhou; L B Lan; J D Schuetz; E G Schuetz; G R Wilkinson Journal: Clin Pharmacol Ther Date: 2001-08 Impact factor: 6.875
Authors: L Becquemont; C Verstuyft; R Kerb; U Brinkmann; M Lebot; P Jaillon; C Funck-Brentano Journal: Clin Pharmacol Ther Date: 2001-10 Impact factor: 6.875
Authors: S Hoffmeyer; O Burk; O von Richter; H P Arnold; J Brockmöller; A Johne; I Cascorbi; T Gerloff; I Roots; M Eichelbaum; U Brinkmann Journal: Proc Natl Acad Sci U S A Date: 2000-03-28 Impact factor: 11.205
Authors: Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg Journal: Discov Med Date: 2012-01 Impact factor: 2.970
Authors: Andrew Owen; Chris Goldring; Paul Morgan; David Chadwick; B Kevin Park; Munir Pirmohamed Journal: Br J Clin Pharmacol Date: 2005-03 Impact factor: 4.335
Authors: Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg Journal: Mol Biotechnol Date: 2010-02 Impact factor: 2.695